DEPLOYThe reference layer for physical AI

Robot model

Evie Ring (and EvieMED)

Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.

Evie Ring (and EvieMED) is a biometric robot built by Movano Health.

pausedPaused. Operational suspension reported by the operator or manufacturer.

Machine-readable surfaces

Form factor
biometric
Maturity stage
commercial
Lifecycle
paused
Deployments
0
ID
39d316cc-181a-452c-b71c-d0a23f695ce4

Specs

notes
[object Object],[object Object],[object Object],[object Object]
specs
TWO rings: Evie Ring (CONSUMER, women's-health-focused: menstrual-cycle tracking, sleep, energy, HR, SpO2, mood/goal trends; GENERAL-WELLNESS) + EvieMED Ring (B2B/clinical variant; FDA 510(k)-cleared pulse oximeter + HR, Dec 2 2024; for clinical trials / remote patient monitoring / payors-pharma). Company: Movano Health (NASDAQ: MOVE; CEO John Mastrototaro).
formFactor
biometric (biometric-primary women's-health smart ring + AI; consumer general-wellness + B2B FDA-cleared variant)

Supply chain

No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.

Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.

Sources (5)

  1. https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html
  2. https://www.mobihealthnews.com/news/movano-health-secures-fda-clearance-eviemed-ring
  3. https://www.sec.gov/Archives/edgar/data/0001734750/000121390025110877/ea0261389-10q_movano.htm
  4. https://www.corvex.ai/blog/press-release-corvex-to-go-public-in-all-stock-merger-withmovano-creating-a-pure-play-platform-for-secure-ai-infrastructure-and-high-performanceinference
  5. https://www.arlnow.com/2026/03/25/va-square-based-ai-company-goes-public-after-merger-with-health-tech-firm/

Common questions

What is Evie Ring (and EvieMED)?
Movano Health (NASDAQ: MOVE; led by chief executive John Mastrototaro) makes the women's-health-focused Evie smart ring, recorded in the biometric form factor, with cycle tracking and women's-health metrics as its editorial differentiator. A load-bearing entity split applies: there are two rings, the consumer Evie Ring, which tracks the menstrual cycle, sleep, energy, heart rate, blood oxygen, and mood as a general-wellness device that is not FDA-cleared, and the separate business-to-business EvieMED Ring, which received an FDA 510(k) clearance for its pulse oximeter and heart rate on December 2, 2024 for clinical trials, remote patient monitoring, and payor and pharma use, with a pivotal study showing accuracy across darker skin tones, so the clearance must not be attributed to the consumer Evie Ring. A significant financial cap-flag is the real risk here: Movano is distressed, with its SEC filings showing going-concern substantial doubt, an accumulated deficit of $160.5 million as of September 30, 2025, cash not sufficient to fund operations beyond the first quarter of 2026 without further capital or a merger, a strategic review and possible sale underway, a one-for-ten reverse stock split in October 2025 to regain NASDAQ compliance, and a $1.5 million bridge loan at an effective rate around 111.6 percent secured by the company's intellectual property that transfers to the lender if a merger fails to close, so the registry records it at commercial maturity but at risk with an active lifecycle and a re-verification flag given the volatile status. A source-drift note: a secondary article cites a stale 2024 cash figure that the SEC filings supersede with the going-concern position, and the company's market-size framing is total-addressable-market language rather than verified revenue.
Who makes Evie Ring (and EvieMED)?
Evie Ring (and EvieMED) is made by Movano Health, based in Pleasanton, California, USA, founded in 2018.
Where is Evie Ring (and EvieMED) deployed?
No verified deployments of Evie Ring (and EvieMED) are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
What is Evie Ring (and EvieMED)'s maturity stage?
Evie Ring (and EvieMED) is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Is Evie Ring (and EvieMED) still being made?
Evie Ring (and EvieMED) is currently paused on the DEPLOY registry: operations are suspended but expected to resume.

Related biometric